St. Jude has been committed to treating and curing sickle cell disease since its opening in 1962.
From birth to adulthood, we help patients live with sickle cell disease, while we continue to research new cures and better long-term care.
The Sickle Cell Disease Portal offers robust genomic and clinical data from cohorts of individuals with sickle cell disease. This data, offered on St. Jude Cloud, is easily and securely available to academic researchers. Genetic modifiers strongly influence outcomes in sickle cell disease. The goal of the Sickle Cell Disease Portal is to promote global collaborative efforts to understand the genetic underpinnings of the disease and develop better therapies.